MACROGENICS, INC. Equity Securities, FV-NI, Realized Gain (Loss)
MACROGENICS, INC. (MGNX) reported Equity Securities, FV-NI, Realized Gain (Loss) of -$7.60 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2019-11-06
- MACROGENICS, INC. equity securities, fv-ni, realized gain (loss) for the quarter ending 2019-09-30 was -$7.60M.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month |
|---|---|
| 2019-09-30 | -$7.60M 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |